Bioxytran (OTCMKTS:BIXT – Get Free Report) released its earnings results on Friday. The company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports.
Bioxytran Stock Down 15.7%
Shares of BIXT stock traded down $0.00 on Friday, reaching $0.02. The company had a trading volume of 68,502 shares, compared to its average volume of 207,919. The business’s 50-day moving average is $0.03 and its 200 day moving average is $0.03. Bioxytran has a one year low of $0.02 and a one year high of $0.09. The stock has a market capitalization of $2.41 million, a PE ratio of -1.05 and a beta of 1.98.
Bioxytran Company Profile
Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.
Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.
Read More
- Five stocks we like better than Bioxytran
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Bioxytran Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioxytran and related companies with MarketBeat.com's FREE daily email newsletter.
